Skip to main content
. Author manuscript; available in PMC: 2015 Nov 28.
Published in final edited form as: J Control Release. 2014 Sep 7;194:197–210. doi: 10.1016/j.jconrel.2014.08.030

Figure 9.

Figure 9

Representative fluorescence images of LS174T s.c. xenograft tumor bearing nude mice after i.v. administration of (A) TAT-gelonin-B4, (B) TAT-gelonin-B4/nIgG-Hep or (C) TAT-gelonin-B4/T84.66-Hep-C5. Tumors in the mice images are indicated by red circles and arrows. Specifically, after administration of TAT-gelonin-B4/T84.66-Hep-C5 complex, the in vivo behaviors of TAT-gelonin-B4 (left image of C) and T84.66-Hep-C5 (right image of C) were simultaneously monitored from the same mice along the time. (TAT-gelonin-B4: Dylight 775-B4 labeled chimeric TAT-gelonin fusion protein, nIgG-Hep: nonspecific IgG-heparin conjugate, T84.66-Hep-C5: Dylight 679-C5 labeled T84.66-heparin conjugate)